Starpharma initiates Phase 1 study for AZD0466 using DEP® platform
Category: #health  By Mateen Dalal  Date: 2019-12-30
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Starpharma initiates Phase 1 study for AZD0466 using DEP® platform

Starpharma, a world leader in dendrimer product development, reportedly announced that AstraZeneca, a renowned British-Swedish biopharmaceutical company, has initiated a phase 1 clinical study of AZD0466. The first patient in this trial has been successfully administered with the drug candidate. The study would enroll patients with an array of cancers and would be conducted in 4-5 U.S. sites.

The AZD0466 development is being conducted under a multi-product license in which Starpharma is eligible to gain launch, development and sales milestones of approximately $124 million. The company is also eligible to get tiered royalties over net sales. Starpharma has received a payment of $3 million triggered from AZD0466’s first dose being administered in the phase 1 study. Under the license, AstraZeneca also finances the development expenses of DEP® AstraZeneca products.

AstraZeneca claims that AZD0466 has the capability to be a ‘best-in-class’ drug in the field. The drug has a wide opportunity in hematological (blood cancers) and solid tumors. This application of the drug is due to its ability to target both Bcl/xL and Bcl2.

Bcl2 is a medically validated oncology target having the Bcl2 inhibitor, VenclextaTM - AbbVie/Genentech (venetoclax), which was approved earlier in 2016 by the US FDA. The peak global sales were estimated to be between $2-3 billion.

Starpharma CEO, Dr Jackie Fairley stated that it is thrilling to reach this crucial milestone both for the company’s partnership with AstraZeneca as well as for Starpharma’s DEP® platform. This is the company’s first collaborated DEP® product to enter the clinic, along with the company’s three internal DEP® products, DEP® cabazitaxel, DEP® irinotecan, and DEP® docetaxel.

Fairley further added that AZD0466 is a great example of the advantages that would be created for new agents utilizing the DEP® platform and the company looks forward to new updates as the study progresses.

In August 2019, the company also observed positive outcomes for its new HER-2 focused DEP® conjugate to treat ovarian cancer.
 

Source credit: https://www.starpharma.com/news/457

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...